Stockreport

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! ...

TScan Therapeutics, Inc.  (TCRX) 
PDF No dose-limiting toxicities observed and infusions of TSC-100 and TSC-101 were well-tolerated across all three dose levels Company to host virtual KOL event featuring [Read more]